DDrare: Database of Drug Development for Rare Diseases

56. ベーチェット病
［臨床試験数：68，薬物数：87（DrugBank：31），標的遺伝子数：36，標的パスウェイ数：113］

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2387066; 3400935113276; 8699505952864; AIN457; APREMILAST; Adalimumab; Allogeneic Stem Cell Transplant; Alpha interferon; Anakinra; Apremilast; Apremilast (CC-10004); Autologous Stem Cell Transplant; Autologous Stem Cell Transplantation; BFGF; CANAKINUMAB; CC; CC-10004; Calcium; Canakinumab; Colchicine; Cyclophosphamide; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine Pill; Cytotoxic Combination; Daclizumab; Dextrose; Entecavir; Etanercept; Etanercept, Methotrexate, Prednisolone; Flucinolone acetonide; GEVOKIZUMAB; GSK1070806; Gevokizumab; Golimumab; Golimumab (GOL); Hemay005; Hydroxychloroquine; IL-2; INTERLEUKIN 2; Ilaris; Infliximab; Interferon Alfa-2A; Interferon alfa; Interferon alfa-2a; Interferon alpha-2a; Interferon-alpha2a; Interleukin 2; Intravitreal Infliximab; J1081; Low-dose IL-2; Methotrexate; Methylorednisolone; Otezla; Other: dextrose water 5%; Other: serum levels of angiogenin, bFGF, VEGF; Pentoxifylline; Prednisolone; Radiation: Diode laser 980nm&100 mWatt; Remicade; Remicade 100 mg; RhumAb to Il-17A (IgG1-k-class); Rituximab; Roferon-A; Roferon-A 3miu; Roferon-A, 3miu; Roferon-A, 4.5miu; Roferon-A, 6miu; Rosuvastatin; Rosuvastatin calcium 40mg; S78989; STELARA; Stelara; Subcutaneous Ustekinumab; TA-650; Thalidomide; Tocilizumab; Tocilizumab (TCZ); Topical Pentoxifylline Gel (Vehicle +PTX); Triamcinolone; Triamcinolone Acetonide; Ustekinumab; Veldona; Veldona,; Water; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03209219 (ClinicalTrials.gov)	June 30, 2017	4/7/2017	Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis	Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis	Behçet Disease;Uveitis	Drug: Interferon Alfa -2A;Drug: Cyclosporine Pill	Peking Union Medical College Hospital	NULL	Recruiting	18 Years	65 Years	All	36	Phase 3	China
2	JPRN-UMIN000025451	2017/04/01	28/12/2016	Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease	Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease	refractory uveitis of Behcet's disease	Patients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.	Yokohama City University Hospital	NULL	Pending	20years-old	65years-old	Male and Female	5	Not selected	Japan
3	NCT00167583 (ClinicalTrials.gov)	November 2004	9/9/2005	Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)	Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)	Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal Vasculitis	Drug: Cyclosporin A;Drug: Interferon-alpha2a	University Hospital Tuebingen	NULL	Completed	18 Years	75 Years	All	37	Phase 3	Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03209219
(ClinicalTrials.gov)

June 30, 2017

4/7/2017

Interferon a2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis

Randomized Prospective Comparative Study of Interferon a2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis

Behçet Disease;Uveitis

Drug: Interferon Alfa -2A;Drug: Cyclosporine Pill

Peking Union Medical College Hospital

NULL

Recruiting

18 Years

65 Years

All

Phase 3

China

JPRN-UMIN000025451

2017/04/01

28/12/2016

Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease

Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease

refractory uveitis of Behcet's disease

Patients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.

Yokohama City University Hospital

NULL

Pending

20years-old

65years-old

Male and Female

Not selected

Japan

NCT00167583
(ClinicalTrials.gov)

November 2004

9/9/2005

Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)

Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)

Behcet's Disease;Panuveitis;Posterior Uveitis;Retinal Vasculitis

Drug: Cyclosporin A;Drug: Interferon-alpha2a

University Hospital Tuebingen

NULL

Completed

18 Years

75 Years

All

Phase 3

Germany